Regeneron Pharmaceuticals
regeneron.com · Healthcare · REGN
Ranked 1,312 of 2,047 companies in the study
- Visibility8
- Citations0
- Sentiment50
- Site quality80
- AI readiness29
AI assistants name Regeneron Pharmaceuticals in 5% of answers, slightly more often than the typical company in its sector. Its overall score is 29 out of 100, ranking 1,312th of 2,047 companies. The company's website passes 4 out of 14 technical checks for readiness with AI tools.
We asked 15 unbranded questions about the healthcare market: none named Regeneron Pharmaceuticals. AI assistants named it in 3 of 60 answers (5.0%). The typical healthcare company is named in 3.3% of answers. By how often it is named, Regeneron Pharmaceuticals ranks 44 of 105 in its sector.
Every dot is a company in the study. Hover one to see it; click to open its report.
This companySame sectorEvery other companyNever named
Five parts, each scored out of 100.
How often AI assistants name the company
How often AI uses the company's own website as a source
How positively AI describes the company
How well built the website's own pages are
How easily AI tools can read and use the website
Visibility is calculated from the answers on this page. How the score is built.
105 companies in this sector. The line on each bar is the typical company.
An answer that names the company
“What are the leading biopharmaceutical companies focused on developing innovative medicines in the US?”
Many biopharmaceutical companies in the U.S. are dedicated to developing innovative medicines. These companies range from established global leaders to emerging biotechs specializing in cutting-edge therapies.
Here are some of the leading biopharmaceutical companies focused on innovative medicines in the U.S.:
Major Biopharmaceutical Companies:
Johnson & Johnson: A global healthcare leader that researches, develops, manufactures, and sells pharmaceutical products for various conditions, including immune diseases, cancer, neurological disorders, and infectious diseases. They have …
The AI’s answer as we received it, shortened and not checked for accuracy.
How the mentions in these answers were split between this company and its rivals
Answers naming it, out of answers received
What this website publishes for an AI agent to read, use and buy from, on a scale of six levels.
- 0
- 1
- 2
- 3
- 4
- 5
Level 1: Basic web presence. Two of robots.txt, a sitemap and Link headers are in place.
- Content Signals
Show every check, for your technical teamHide the checks
- study: 92.0%robots.txtPassed
A valid robots.txt with crawl rules at the site root.
- study: 86.8%SitemapPassed
An XML sitemap listing the pages, ideally referenced from robots.txt.
- study: 0.3%Link headersNot met
Send Link headers such as rel="api-catalog" or rel="describedby" on the homepage.
- study: 5.5%DNS for AI DiscoveryNot present
Advertise agent endpoints with SVCB records under _agents.
- study: 1.9%Markdown negotiationNot met
Return a markdown version when asked with Accept: text/markdown, for example at the CDN.
- study: 25.1%llms.txtNot met
Publish an llms.txt with a short summary and the key links.
- study: 93.4%AI bot rulesPassed
Explicit robots.txt rules for AI crawlers such as GPTBot, ClaudeBot and PerplexityBot.
- study: 1.4%Content SignalsNot met
Add a Content-Signal line for search, ai-input and ai-train to robots.txt.
- study: 0.2%Web Bot AuthNot present
Only relevant if you run your own agents or crawlers: publish a signing key directory.
- study: 0.3%API CatalogNot met
List public APIs in a linkset at /.well-known/api-catalog.
- study: 11.8%OAuth discoveryNot met
Publish OpenID Connect or OAuth server metadata under /.well-known.
- study: 10.3%OAuth Protected ResourceNot met
Serve protected resource metadata at /.well-known/oauth-protected-resource.
- study: 0.0%auth.mdNot met
Publish an auth.md describing how agents sign in.
- study: 0.2%MCP Server CardNot met
Offer an MCP server and publish its server card under /.well-known.
- study: 0.1%A2A Agent CardNot met
Publish an agent card at /.well-known/agent-card.json.
- study: 0.2%Agent SkillsNot met
Publish a skills index with the main tasks agents can do.
- study: 33.7%WebMCPCould not check
Register key actions such as search or cart as WebMCP tools.
- study: 0.1%ARD manifestNot met
Publish an ai-catalog.json listing every agent interface.
Score 32 of 100 · 97% of checks could run · checked on October 5, 2026 · www.regeneron.com · 2,047 companies scanned
4 of 14 passed. This list is for your technical team. The percentage is how many companies in the study pass each check.
These 14 checks ran during the audit and are what the AI readiness part of the overall score counts. The scan above ran later and is stricter on Link headers and Markdown, so a check can pass here and not there.
Show the 14 checksHide them
- Passedrobots.txt publishedstudy: 85.0%
- PassedXML sitemapstudy: 73.2%
- Not metHTTP Link headers (RFC 8288)study: 29.0%
- Not metMarkdown content negotiationstudy: 8.3%
- Not metllms.txt publishedstudy: 21.7%
- PassedToken budget (page weight)study: 95.2%
- PassedExplicit AI bot rulesstudy: 13.0%
- Not metAPI Catalog (.well-known/api-catalog)study: 0.2%
- Not metOAuth Authorization Server discoverystudy: 10.1%
- Not metOAuth Protected Resource discoverystudy: 9.3%
- Not metMCP Server Cardstudy: 0.0%
- Not metA2A Agent Cardstudy: 0.0%
- Not metWebMCP toolsstudy: 4.2%
- Not metAgent Skills declaredstudy: 0.0%
This website sets rules for 12 AI crawlers by name. All others follow its general rules.
- GPTBot*partly
- ClaudeBot*partly
- Anthropic-AIpartly
- Google-Extended*partly
- Applebot-Extended*partly
- Meta-ExternalAgent*partly
- FacebookBotpartly
- Bytespider*partly
- CCBot*partly
- Diffbot*partly
- Omgilibotpartly
- OAI-SearchBotpartly
- Claude-SearchBotpartly
- PerplexityBot*partly
- Applebotpartly
- Amazonbot*partly
- YouBotpartly
- ChatGPT-User*partly
- Claude-Userpartly
- Perplexity-User*partly
- DuckAssistBotpartly
- MistralAI-Userpartly
Read from the website’s own rules file (robots.txt). An asterisk marks a crawler the file names. The rest follow its general rules. “Partly” means only some pages are blocked.
How many times each website was listed as a source in these answers
In the study as S&P 500.
- How to identify companies specializing in harmonizing technology and biology for new medicine development?
- What are the leading biopharmaceutical companies focused on developing innovative medicines in the US?
- What to do if you experience side effects from newly approved biologic therapies?
- Alternatives to biologic therapies for managing chronic diseases
- Best ways to find clinical trials for advanced medical therapies in the United States
- Typical price range for novel biologic therapies in the US healthcare market
- How to find patient support for navigating access to cutting-edge medical treatments?
- What options are available besides clinical trial participation for accessing advanced treatments?
- Who can benefit most from personalized medicine approaches derived from genetic research?
- How are advanced biologics being used in the treatment of autoimmune disorders?
- Biopharmaceutical vs biotechnology companies for rare disease treatment research
- How does insurance coverage usually work for new therapies approved in the biopharmaceutical field?
- Are therapies developed using advanced genetics platforms generally worth their higher cost?
- Is investing in companies with integrated research and technology platforms a good idea for long-term growth?
- How do traditional pharmaceutical companies compare to science-driven biopharmaceutical firms in terms of drug discovery and innovation?
Columns, left to right: OpenAI, Claude, Perplexity, Gemini. The AI assistants often disagree. Across the study, on 40% of the questions where a company is named, only one of the four names it.
A badge of this result that you can show on your own website. Copy the code below.
<a href="https://aeo-audit.rezolve.com/us/regeneron.com"><img src="https://aeo-audit.rezolve.com/us/badges/regeneron.com.svg" alt="Overall score 29 of 100, US AI Visibility Study 2026" width="280" height="64"></a>